0001437749-22-005774.txt : 20220309 0001437749-22-005774.hdr.sgml : 20220309 20220309212111 ACCESSION NUMBER: 0001437749-22-005774 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220224 FILED AS OF DATE: 20220309 DATE AS OF CHANGE: 20220309 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rice Michael CENTRAL INDEX KEY: 0001389512 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 22727193 MAIL ADDRESS: STREET 1: C/O BIOLIFE SOLUTIONS, INC. STREET 2: 171 FRONT STREET CITY: OWEGO STATE: NY ZIP: 13827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 rdgdoc.xml FORM 4 X0306 4 2022-02-24 0000834365 BIOLIFE SOLUTIONS INC BLFS 0001389512 Rice Michael C/O BIOLIFE SOLUTIONS, INC. 3303 MONTE VILLA PARKWAY, SUITE 310 BOTHELL WA 98021 1 1 CEO Common Stock 2022-02-24 4 A 0 70094 A 328859 D Restricted Stock Award 0 2022-02-24 4 A 0 70094 0 A Common Stock 70094 70094 D The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2022 compensation. The amount represented in Column 5 of Table I reflects the amount of securities beneficially owned by the reporting person as of the transaction date reported herein. It does not give effect to the transaction reported by the reporting person on the Form 4 filed by the reporting person on March 3, 2022. The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. /s/ Michael Rice 2022-03-09